Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Xcyte Digital Corp. Signs Agreement to Purchase Assets of Webinar.net (click to learn more) Viva Gold Reports Multiple High-Grade Gold Hits at the Tonopah Gold Project (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News First Wave BioPharma Inc FWBI

Healthcare Biotechnology
First Wave BioPharma, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal (GI) diseases. It is focused on developing a therapeutic pipeline with multiple late-stage clinical programs built around three proprietary technologies: Latiglutenase, a targeted... see more

Recent & Breaking News (NDAQ:FWBI)

First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $4.0 Million Gross Proceeds Priced At-the-Market

GlobeNewswire September 14, 2023

First Wave BioPharma Announces Exclusive Global License Agreement for Capeserod from Sanofi

GlobeNewswire September 14, 2023

First Wave BioPharma to Participate in the H.C. Wainwright 25th Annual Global Investment Conference

GlobeNewswire September 5, 2023

First Wave BioPharma, Inc. Announces Pricing of $2.1 Million Public Offering

GlobeNewswire July 19, 2023

First Wave BioPharma Announces Initial Topline Results from Phase 2 SPAN Clinical Trial Investigating Enhanced Adrulipase Formulation

GlobeNewswire July 13, 2023

First Wave BioPharma Chairman and CEO Issues Letter to Stockholders

GlobeNewswire July 5, 2023

First Wave BioPharma Announces Final Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation

GlobeNewswire June 28, 2023

First Wave BioPharma Strengthens Intellectual Property Estate

GlobeNewswire June 27, 2023

First Wave BioPharma to Attend the 36th National Cystic Fibrosis Education Conference (July 28-30)

GlobeNewswire June 15, 2023

First Wave BioPharma Announces Exercise of Warrants and Issuance of New Warrants in a Private Placement for $2.4 Million Gross Proceeds Priced At-the-Market

GlobeNewswire June 13, 2023

First Wave BioPharma Reaches Enrollment Target for Phase 2 SPAN Adrulipase Clinical Trial in Cystic Fibrosis

GlobeNewswire June 13, 2023

First Wave BioPharma CEO James Sapirstein to Present at 2023 BIO International Conference

GlobeNewswire May 15, 2023

First Wave BioPharma Completes Patient Screening For Phase 2 Span Adrulipase Clinical Trial in Cystic Fibrosis

GlobeNewswire May 11, 2023

First Wave BioPharma to Participate in EF Hutton Inaugural Global Conference

GlobeNewswire May 2, 2023

First Wave Biopharma Exceeds 50% Enrollment Target for Phase 2 Span Adrulipase Clinical Trial in Cystic Fibrosis

GlobeNewswire April 25, 2023

First Wave BioPharma Announces $4.0 Million Private Placement Priced At-The-Market under Nasdaq Rules

GlobeNewswire March 13, 2023

HOOKIPA Pharma Appoints Terry Coelho to its Board of Directors

GlobeNewswire March 13, 2023

First Wave BioPharma Announces Second Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation in Cystic Fibrosis

GlobeNewswire March 10, 2023

First Wave BioPharma Announces First Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation

GlobeNewswire March 9, 2023

First Wave BioPharma to Participate in 'Fireside Chat' at the 35th Annual Roth Conference

GlobeNewswire February 28, 2023